Assessment of Interstitial Lung Disease in Rheumatoid Arthritis by Lung Ultrasound

The high resolution chest scan is the gold standard for the screening of interstitial lung disease, but this remains an onerous examination, and irradiating.

Ultrasound could be used to detect these disorders with a very good sensitivity and specificity. This exam offers the advantage of being non radiating, inexpensive, and accessible to the rheumatologist who already uses it in their daily practice.

The investigators want to assess the lung ultrasound performance compared with the gold standard.

Patients will be included during a regular follow-up consultation with their referent rheumatologist. If there is an indication of first line biotherapy or targeted therapy the doctor will propose to the patient to participate in the study, give him the information leaflet, collect orally non-opposition, and will complete a survey for evaluation of the general health and potential risk factors for interstitial lung.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Diseases Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Lung Diseases, Interstitial Musculoskeletal Diseases Respiratory Tract Diseases Rheumatic Diseases Rheumatoid Arthritis Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service de Rhumatologie. Centre hospitalier Lyon Sud. 69310

Pierre-Bénite, 69310, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men and women over the age of 18
With rheumatoid arthritis meeting the criteria ACR (American College of Rheumatology)/ EULAR (EUropean League Against Rheumatism) 2010
Never received any biotherapy or targeted therapy
Having an indication of introduction of biotherapy or therapy targeted (JAK inhibitors) (JAK : Janus kinase)

Exclusion criteria

Refusal to participate in the study
Known pulmonary disease that can alter lung interstitium: cardiac decompensation, COPD (chronic obstructive pulmonary disease), thoracic surgery, infection pulmonary
Patient with respiratory functional signs suggestive of PID (Diffuse interstitial lung disease)
Patient with signs of cardiac decompensation
Patient with pulmonary auscultation suggestive of PID
Pregnant or lactating woman
Psychiatric pathology seriously hindering understanding
Difficulty understanding oral French
Person deprived of liberty or under legal protection

Treatment and study plan

Lung sonography

Other

Realization of a lung sonography with scoring of the number of B-lines exploring 14 intercostal spaces.

Duration of the exam : twenty minutes. Recording for a second analysis by another lung specialist.

Primary outcomes

Sensibility and specificity of the lung sonography for interstitial lung disease screening in rheumatoid arthritis patients.

Time frame: Month 12

To estimate the sensitivity and specificity of pulmonary ultrasound compared to CT scans in patients with rheumatoid arthritis consulting at the Lyon South Hospital Centre or the Edouard Herriot Hospital for the start-up of biotherapy or targeted therapy. (CT : computerized tomography)

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: PO-PID

Important dates

Study start: 2020
Primary completion: 2024
Study completion: 2024
First posted: Dec 12, 2019
Registry last updated: Oct 10, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed